« Return to News | Clinical Intelligence

EMA objects to Alexza’s Adasuve MAA

Tuesday, February 14, 2012 07:18 AM

Alexza Pharmaceuticals has received preliminary feedback, the Day 80 Assessment Report, from the European Medicines Agency (EMA) regarding its Marketing Authorization Application (MAA) for Adasuve, which seeks approval for the rapid control of agitation in adult patients with schizophrenia or bipolar disorder.

The EMA’s assessment report of Adasuve (Staccato loxapine) outlines major objections pertaining to the extrapolation of the phase III study population to the intended patient population, and pulmonary safety in patients with active airways disease. The EMA gave recommendations to address these issues via the risk management plan, other aspects of the risk management plan and the need to obtain an EU GMP certificate for the Alexza manufacturing facility and commercial manufacturing process. 

The next official EMA communication Alexza expects to receive will be the Day 120 notification and report, when the Committee for Medicinal Products for Human Use (CHMP) finalizes the list of review questions, the overall conclusions of scientific data and a listing of outstanding issues.

Alexza completed a Pre-Approval Inspection of its GMP commercial manufacturing facility by the FDA in December 2011 and believes it is well prepared for the EMA inspection of its facility.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.